Compared with their TCF1+TOX+ counterparts, a TCF1+TOX− subset in the draining lymph node of the tumor is protected from the epigenetic scar of exhaustion and demonstrates superior antitumor immunity in adoptive cell therapy and PD-1 blockade [51]. This evidence concerns the gene TCF7 and neoplasm.